Viewing StudyNCT02401347

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 3:53 AM
Last Modification Date: 2024-10-26 @ 11:40 AM
Study NCT ID: NCT02401347
Status: COMPLETED
Last Update Posted: 2023-02-21
First Post: 2015-03-24
Brief Title: Phase II Trial of Talazoparib in BRCA12 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Sponsor: Melinda Telli
Organization: Stanford University
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Triple-Negative Breast Cancer
Advanced Breast Cancer
HER2Neu Negative
Keywords:
Name View
PALB2 mutation View
BRIP1 mutation View
BARD1 mutation View
Rad51c mutation View
PTEN mutation View
CHEK2 mutation View
ATM mutation View
NBN mutation View
Rad51d mutation View
Rad50 mutation View
MRE11 mutation View
FANC mutation View
HRD assay score View
ATR mutation View